GB Sciences (GB Sciences) Operating Income : $-1.58 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Operating Income?

GB Sciences's Operating Income for the three months ended in Dec. 2023 was $-0.23 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.58 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. GB Sciences's Operating Income for the three months ended in Dec. 2023 was $-0.23 Mil. GB Sciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, GB Sciences's Operating Margin % for the quarter that ended in Dec. 2023 was %.

GB Sciences's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GB Sciences's annualized ROC % for the quarter that ended in Dec. 2023 was -65.39%. GB Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

GB Sciences Operating Income Historical Data

The historical data trend for GB Sciences's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Operating Income Chart

GB Sciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Operating Income

Get a 7-Day Free Trial

-13.19

-7.37

-2.00

-1.87

-1.67

GB Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Income	Get a 7-Day Free Trial															-0.41	-0.53	-0.27	-0.55	-0.23

GB Sciences Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.58 Mil.

GB Sciences (OTCPK:GBLX) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GB Sciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-0.936 * ( 1 - 0% )	/	( (1.426	+	1.437)	/ 2 )
=	-0.936	/	1.4315
=	-65.39 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.234	-	3.426	-	( 0.105	-	max(0, 4.852	-	0.234	+	0.105	))
=	1.426

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.147	-	3.482	-	( 0.017	-	max(0, 4.919	-	0.147	+	0.017	))
=	1.437

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

GB Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.596	/	( ( (0 + max(-3.296, 0))	+	(0 + max(-3.352, 0)) )	/	2 )
=	-0.596	/	( ( 0	+	0 )	/	2 )
=	-0.596	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.129)	-	(3.426	+	0	+	-0.00099999999999945)
=	-3.296

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.13)	-	(3.482	+	0	+	-8.8817841970013E-16)
=	-3.352

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

GB Sciences's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.234	/	0
	=	%

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.

Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.

GB Sciences Operating Income Related Terms

Thank you for viewing the detailed overview of GB Sciences's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.

GB Sciences (GB Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Operating Income

Comparable Companies

Traded in Other Exchanges

18C:Germany

Address

9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148

Website

https://www.gbsciences.com

GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.

Executives

John C Poss	director, officer: Chief Executive Officer
Craig Ellins	director, 10 percent owner, officer: CEO	3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp	10 percent owner	C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp	10 percent owner	C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus	10 percent owner	260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206